Neuropeptide W Exhibits Preventive and Therapeutic Effects on Acetic Acid-Induced Colitis via Modulation of the Cyclooxygenase Enzyme System.
Cyclooxygenases
Inflammation
Neuropeptide W
Oxidative injury
Ulcerative colitis
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
13
09
2022
accepted:
21
12
2022
medline:
18
5
2023
pubmed:
12
1
2023
entrez:
11
1
2023
Statut:
ppublish
Résumé
The novel peptide neuropeptide W (NPW) was originally shown to function in the control of feeding behavior and energy homeostasis. The aim of this study was to elucidate the putative preventive and therapeutic effects of NPW on colitis-associated oxidative injury and the underlying mechanisms for its action. Sprague-Dawley rats in the acute colitis groups received NPW (0.5, 1 or 5 µg/kg/day) injections prior to induction of colitis with acetic acid, while the chronic colitis groups were treated after the induction of colitis. In both acute and chronic colitis (CC) groups, treatments were continued for 5 days and the rats were decapitated at the 24th hour of the last injections and colon tissues were collected for assessments. NPW pretreatment given for 5 days before colitis induction, as well as treating rats with NPW during the 5-day course of CC, abolished colonic lipid peroxidation. NPW treatment prevented colitis-induced reduction in blood flow, diminished neutrophil infiltration, and pro-inflammatory cytokine responses. NPW pretreatment only at the higher dose reduced colonic edema and microscopic score and preserved colonic glutathione stores. Elevations in cyclooxygenase (COX) enzyme activity and COX-1 protein level during the acute phase of colitis as well as reduction in COX-2 were all reversed with NPW pretreatment. In contrast, NPW treatment was effective in reducing the elevated COX-2 concentration during the chronic phase. NPW alleviates acetic acid-induced oxidative colonic injury in rats through the upregulation of colonic blood flow as well as the inhibition of COX-2 protein expression and pro-inflammatory cytokine production.
Sections du résumé
BACKGROUND
The novel peptide neuropeptide W (NPW) was originally shown to function in the control of feeding behavior and energy homeostasis. The aim of this study was to elucidate the putative preventive and therapeutic effects of NPW on colitis-associated oxidative injury and the underlying mechanisms for its action.
METHODS
Sprague-Dawley rats in the acute colitis groups received NPW (0.5, 1 or 5 µg/kg/day) injections prior to induction of colitis with acetic acid, while the chronic colitis groups were treated after the induction of colitis. In both acute and chronic colitis (CC) groups, treatments were continued for 5 days and the rats were decapitated at the 24th hour of the last injections and colon tissues were collected for assessments.
RESULTS
NPW pretreatment given for 5 days before colitis induction, as well as treating rats with NPW during the 5-day course of CC, abolished colonic lipid peroxidation. NPW treatment prevented colitis-induced reduction in blood flow, diminished neutrophil infiltration, and pro-inflammatory cytokine responses. NPW pretreatment only at the higher dose reduced colonic edema and microscopic score and preserved colonic glutathione stores. Elevations in cyclooxygenase (COX) enzyme activity and COX-1 protein level during the acute phase of colitis as well as reduction in COX-2 were all reversed with NPW pretreatment. In contrast, NPW treatment was effective in reducing the elevated COX-2 concentration during the chronic phase.
CONCLUSIONS
NPW alleviates acetic acid-induced oxidative colonic injury in rats through the upregulation of colonic blood flow as well as the inhibition of COX-2 protein expression and pro-inflammatory cytokine production.
Identifiants
pubmed: 36631709
doi: 10.1007/s10620-022-07811-2
pii: 10.1007/s10620-022-07811-2
doi:
Substances chimiques
Cyclooxygenase 2
EC 1.14.99.1
Acetic Acid
Q40Q9N063P
Cytokines
0
Peroxidase
EC 1.11.1.7
Neuropeptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2441-2453Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Feldman M, Friedman LS, Brandt LJ, Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management, Elsevier Health Sciences 2020.
Blonski W, Buchner AM, Lichtenstein GR. Treatment of ulcerative colitis. Curr Opin Gastroenterol 2014;30:84–96.
pubmed: 24285003
doi: 10.1097/MOG.0000000000000031
Jairath V, Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol 2020;5:2–3.
pubmed: 31648974
doi: 10.1016/S2468-1253(19)30358-9
Kumar S, Kumar A, Microbial pathogenesis in inflammatory bowel diseases. Microb Pathog 2021;105383.
Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713–1725.
pubmed: 22047562
doi: 10.1056/NEJMra1102942
Ghatule R, Shalini G, Gautam M, Singh A, Joshi V, Goel R. Effect of Azadirachta indica leaves extract on acetic acid-induced colitis in rats: Role of antioxidants, free radicals and myeloperoxidase. Asian Pac J Trop Dis 2012;2:S651–S657.
doi: 10.1016/S2222-1808(12)60238-2
Hadji H, Bouchemal K, Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems. Adv Drug Deliv Rev 2022;114101.
Jena G, Trivedi PP, Sandala B. Oxidative stress in ulcerative colitis: an old concept but a new concern. Free Radic Res 2012;46:1339–1345.
pubmed: 22856328
doi: 10.3109/10715762.2012.717692
Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998;115:297–306.
pubmed: 9679035
doi: 10.1016/S0016-5085(98)70196-9
Tian T, Wang Z, Zhang J, Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid Med Cell Longev 2017;2017.
Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344–1367.
pubmed: 7557106
doi: 10.1016/0016-5085(95)90599-5
Fabia R, Willén R, Ar’Rajab A, Andersson R, Ahrén B, Bengmark S. Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis. Eur Surg Res 1992;24:211–225.
pubmed: 1505598
doi: 10.1159/000129209
Kornbluth A, Sachar D, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, practice parameters committee. Am J Gastroenterol 2010;105: 501–23.
Baumgart DC. The diagnosis and treatment of Crohn’s disease and ulcerative colitis. Dtsch Ärztebl Int 2009;106:123.
pubmed: 19568370
pmcid: 2695363
Shimomura Y, Harada M, Goto M et al. Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem 2002;277:35826–35832.
pubmed: 12130646
doi: 10.1074/jbc.M205337200
Takenoya F, Kageyama H, Hirako S et al. Neuropeptide W. Front Endocrinol 2012;3:171.
doi: 10.3389/fendo.2012.00171
Chottova Dvorakova M. Distribution and function of neuropeptides W/B signaling system. Front Physiol 2018;9:981.
pubmed: 30087623
pmcid: 6067035
doi: 10.3389/fphys.2018.00981
Mondal MS, Yamaguchi H, Date Y et al. A role for neuropeptide W in the regulation of feeding behavior. Endocrinology 2003;144:4729–4733.
pubmed: 12959997
doi: 10.1210/en.2003-0536
Yan F, Wang R, Li S et al. FoxO3a suppresses neuropeptide W expression in neuronal cells and in rat hypothalamus and its implication in hypothalamic–pituitary–adrenal (HPA) axis. Int J Biol Sci 2020;16:2775.
pubmed: 33061795
pmcid: 7545709
doi: 10.7150/ijbs.45619
Ji L, Zhu H, Chen H et al. Modulation of CaV1.2 calcium channel by neuropeptide W regulates vascular myogenic tone via G protein-coupled receptor 7. J Hypertens 2015;33:2431–2442.
pubmed: 26536090
doi: 10.1097/HJH.0000000000000723
Pate AT, Yosten GL, Samson WK. Neuropeptide W increases mean arterial pressure as a result of behavioral arousal. Am J Physiol Regul Integr Comp Physiol 2013;305:R804–R810.
pubmed: 23926134
pmcid: 3798801
doi: 10.1152/ajpregu.00119.2013
Yu N, Chu C, Kunitake T, Kato K, Nakazato M, Kannan H. Cardiovascular actions of central neuropeptide W in conscious rats. Regul Pept 2007;138:82–86.
pubmed: 17011641
doi: 10.1016/j.regpep.2006.08.003
Niimi M, Murao K. Neuropeptide W as a stress mediator in the hypothalamus. Endocrine 2005;27:51–54.
pubmed: 16077171
doi: 10.1385/ENDO:27:1:051
Takenoya F, Wang L, Kageyama H et al. Neuropeptide W-induced hypophagia is mediated through corticotropin-releasing hormone-containing neurons. J Mol Neurosci 2015;56:789–798.
pubmed: 25691152
doi: 10.1007/s12031-015-0501-1
Xing Y, Liu Y, Deng M et al. The synergistic effects of opioid and neuropeptide B/W in rat acute inflammatory and neuropathic pain models. Eur J Pharmacol 2021;898:173979.
pubmed: 33639195
doi: 10.1016/j.ejphar.2021.173979
Yamamoto T, Saito O, Shono K, Tanabe S. Anti-hyperalgesic effects of intrathecally administered neuropeptide W-23, and neuropeptide B, in tests of inflammatory pain in rats. Brain Res 2005;1045:97–106.
pubmed: 15910767
doi: 10.1016/j.brainres.2005.03.027
Atici AE, Arabacı Tamer S, Levent HN et al. Neuropeptide W attenuates oxidative multi-organ injury in rats induced with intra-abdominal sepsis. Inflammation 2022;45:279–296.
pubmed: 34564825
doi: 10.1007/s10753-021-01545-5
Arabacı Tamer S, Akbulut S, Peker Eyüboğlu İ et al. Peripheral administration of Neuropeptide-W protects against stress-induced gastric injury in rats. Life Sci 2022;310:121087.
pubmed: 36252697
doi: 10.1016/j.lfs.2022.121087
Koyuncuoglu T, Ipek BE, Dertsiz EK, Akakin D, Yuksel M, Yegen BC, The neuroprotective effects of neuropeptide W in newborn rats with cerebral palsy, Acta Physiologica, Wiley, 2019, pp. 87–87.
Tamer SA, Akbulut S, Akakin D, Yegen BC, Protective effects of neuropeptide-W on stress-induced gastric ulcer in rats, Acta Physiologica, Wiley, 2019, pp. 116–116.
Özdemir ZN, Gökhan T, Pınar K et al. Nicotine alleviates colitis-induced damage in rats via its anti-oxidative activity. Marmara Med J 2014;27:13–20.
doi: 10.5472/MMJ.2013.03125.1
Ahn H, Lindhagen J, Lundgren O. Measurement of colonic blood flow with laser Doppler flowmetry. Scand J Gastroenterol 1986;21:871–880.
pubmed: 2946071
doi: 10.3109/00365528609011132
Arabacı Tamer S, Üçem S, Büke B et al. Regular moderate exercise alleviates gastric oxidative damage in rats via the contribution of oxytocin receptors. J Physiol 2020;598:2355–2370.
pubmed: 32266969
doi: 10.1113/JP279577
Cooper HS, Murthy S, Shah R, Sedergran D. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238–249.
pubmed: 8350599
Farghaly HS, Thabit RH. L-Arginine and aminoguanidine reduce colonic damage of acetic acid-induced colitis in rats: Potential modulation of nuclear factor-κB/p65. Clin Exp Pharmacol Physiol 2014;41:769–779.
pubmed: 25224370
doi: 10.1111/1440-1681.12287
Tuğtepe H, Şener G, Bıyıklı NK et al. The protective effect of oxytocin on renal ischemia/reperfusion injury in rats. Regul Pept 2007;140:101–108.
pubmed: 17261335
doi: 10.1016/j.regpep.2006.11.026
Arabacı Tamer S, Yıldırım A, Arabacı Ş et al. Treatment with estrogen receptor agonist ERβ improves torsion-induced oxidative testis injury in rats. Life Sci 2019;222:203–211.
pubmed: 30825546
doi: 10.1016/j.lfs.2019.02.056
Gue M, Bonbonne C, Fioramonti J et al. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. Am J Physiol Gastrointest Liver Physiol 1997;272:G84–G91.
doi: 10.1152/ajpgi.1997.272.1.G84
Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307–317.
pubmed: 21677747
pmcid: 3204665
doi: 10.1038/nature10209
Dembiński A, Warzecha Z, Ceranowicz P et al. Synergic interaction of rifaximin and mutaflor (Escherichia coli Nissle 1917) in the treatment of acetic acid-induced colitis in rats. Gastroenterol Res Pract 2016;2016:3126280.
pubmed: 27433160
pmcid: 4940557
doi: 10.1155/2016/3126280
Jurjus AR, Khoury NN, Reimund J-M. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004;50:81–92.
pubmed: 15385082
doi: 10.1016/j.vascn.2003.12.002
Randhawa PK, Singh K, Singh N, Jaggi AS. A review on chemical-induced inflammatory bowel disease models in rodents. Kor J Physiol Pharmacol 2014;18:279–288.
doi: 10.4196/kjpp.2014.18.4.279
Rodríguez Basso A, Carranza A, Zainutti VM, Bach H, Gorzalczany SB. Pharmacological activity of peperina (Minthostachys verticillata) on gastrointestinal tract. J Ethnopharmacol 2021;269:113712.
pubmed: 33352243
doi: 10.1016/j.jep.2020.113712
Essel LB, Obiri DD, Osafo N, Antwi AO, Duduyemi MB. Ulcerative colitis induced with acetic acid is ameliorated by Antrocaryon micraster through reduced serum levels of tumor necrosis factor alpha and interleukin‑6 in Sprague Dawley rats. Pharmacognosy Res 2020;12.
Ahmed O, Farid A, Elamir A. Dual role of melatonin as an anti-colitis and anti-extra intestinal alterations against acetic acid-induced colitis model in rats. Sci Rep 2022;12:6344.
pubmed: 35428860
pmcid: 9012815
doi: 10.1038/s41598-022-10400-y
Carty E, De Brabander M, Feakins RM, Rampton DS. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000;46:487–492.
pubmed: 10716677
pmcid: 1727893
doi: 10.1136/gut.46.4.487
El-Akabawy G, El-Sherif NM. Zeaxanthin exerts protective effects on acetic acid-induced colitis in rats via modulation of pro-inflammatory cytokines and oxidative stress. Biomed Pharmacother 2019;111:841–851.
pubmed: 30616083
doi: 10.1016/j.biopha.2019.01.001
Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635–646.
pubmed: 22357456
doi: 10.1038/clpt.2011.328
Esworthy RS, Aranda R, Martín MG, Doroshow JH, Binder SW, Chu FF. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol 2001;281:G848–G855.
pubmed: 11518697
doi: 10.1152/ajpgi.2001.281.3.G848
Kruidenier L, van Meeteren ME, Kuiper I et al. Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic Biol Med 2003;34:753–765.
pubmed: 12633752
doi: 10.1016/S0891-5849(02)01426-0
Çevik Ö, Şener A, Kumral ZÖ et al. Protective and therapeutic effects of Polygonum cognatum Meissn aqueous extract in experimental colitis. Marmara Pharmaceut J 2014;18:126–134.
doi: 10.12991/mpj.2014187239
Motawea MH, Abd Elmaksoud HA, Elharrif MG, Desoky AAE, Ibrahimi A. Evaluation of anti-inflammatory and antioxidant profile of oleuropein in experimentally induced ulcerative colitis. Int J Mol Cell Med 2020;9:224.
pubmed: 33274185
pmcid: 7703659
Chami B, Ahmad G, Schroder A, San Gabriel P, Witting P. the role of myeloperoxidase and neutrophil extracellular traps in the pathogenesis of inflammatory bowel disease. Gastroenterology 2021;160:S5–S6.
doi: 10.1053/j.gastro.2021.01.044
Hansberry DR, Shah K, Agarwal P, Agarwal N, Fecal myeloperoxidase as a biomarker for inflammatory bowel disease. Cureus 2017;9.
Ahmad G, Chami B, Liu Y et al. The synthetic myeloperoxidase inhibitor AZD3241 ameliorates dextran sodium sulfate stimulated experimental colitis. Front Pharmacol 2020;11:556020.
pubmed: 33041796
pmcid: 7522858
doi: 10.3389/fphar.2020.556020
Ando H, Ukena K, Nagata S, Handbook of hormones: comparative endocrinology for basic and clinical research, Academic 2021.
Hochol A, Belloni AS, Rucinski M et al. Expression of neuropeptides B and W and their receptors in endocrine glands of the rat. Int J Mol Med 2006;18:1101–1106.
pubmed: 17089014
Saijo H, Tatsumi N, Arihiro S et al. Microangiopathy triggers, and inducible nitric oxide synthase exacerbates dextran sulfate sodium-induced colitis. Lab Invest 2015;95:728–748.
pubmed: 25938626
doi: 10.1038/labinvest.2015.60
Hultén L, Lindhagen J, Lundgren O, Fasth S, Ahrén C. Regional intestinal blood flow in ulcerative colitis and Crohn’s disease. Gastroenterology 1977;72:388–396.
pubmed: 832785
doi: 10.1016/S0016-5085(77)80245-X
Leung FW, Koo A. Mucosal vascular stasis precedes loss of viability of endothelial cells in rat acetic acid colitis. Dig Dis Sci 1991;36:727–732.
pubmed: 2032512
doi: 10.1007/BF01311228
Chottova Dvorakova M. Distribution and function of neuropeptides W/B signaling system. Front Physiol 2018;9:981.
pubmed: 30087623
pmcid: 6067035
doi: 10.3389/fphys.2018.00981
Ferrer R, Moreno JJ. Role of eicosanoids on intestinal epithelial homeostasis. Biochem Pharmacol 2010;80:431–438.
pubmed: 20457139
doi: 10.1016/j.bcp.2010.04.033
Le Loupp AG, Bach-Ngohou K, Bourreille A et al. Activation of the prostaglandin D2 metabolic pathway in Crohn’s disease: involvement of the enteric nervous system. BMC Gastroenterol 2015;15:112.
pubmed: 26338799
pmcid: 4558965
doi: 10.1186/s12876-015-0338-7
Melgar S, Drmotova M, Rehnström E, Jansson L, Michaëlsson E. Local production of chemokines and prostaglandin E2 in the acute, chronic and recovery phase of murine experimental colitis. Cytokine 2006;35:275–283.
pubmed: 17088072
doi: 10.1016/j.cyto.2006.09.007
Vong L, Ferraz JG, Panaccione R, Beck PL, Wallace JL. A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci USA 2010;107:12023–12027.
pubmed: 20547854
pmcid: 2900663
doi: 10.1073/pnas.1004982107
Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol 2001;96:635–643.
pubmed: 11280528
doi: 10.1111/j.1572-0241.2001.03671.x
Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol 2009;65:963–970.
pubmed: 19711064
doi: 10.1007/s00228-009-0719-3
Singh VP, Patil CS, Jain NK, Kulkarni SK. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacology 2004;72:77–84.
pubmed: 15331912
doi: 10.1159/000079135
Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29:781–788.
pubmed: 19946329
doi: 10.1038/onc.2009.421
Aryannejad A, Tabary M, Noroozi N et al. Anti-inflammatory effects of ivermectin in the treatment of acetic acid-induced colitis in rats: involvement of GABA(B) receptors. Dig Dis Sci 2022;67:3672–3682.
pubmed: 34674071
doi: 10.1007/s10620-021-07258-x
Camacho-Barquero L, Villegas I, Sánchez-Calvo JM et al. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 2007;7:333–342.
pubmed: 17276891
doi: 10.1016/j.intimp.2006.11.006
Dudhgaonkar SP, Tandan SK, Kumar D, Raviprakash V, Kataria M. Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Inflammopharmacology 2007;15:188–195.
pubmed: 17943250
doi: 10.1007/s10787-007-1603-3
El-Medany A, Mahgoub A, Mustafa A, Arafa M, Morsi M. The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. Eur J Pharmacol 2005;507:291–299.
pubmed: 15659320
doi: 10.1016/j.ejphar.2004.11.036
Lee Y, Kim W, Hong S et al. Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages. Eur J Pharmacol 2014;726:49–56.
pubmed: 24462351
doi: 10.1016/j.ejphar.2014.01.011
Kjærgaard S, Damm MMB, Chang J, et al. Altered structural expression and enzymatic activity parameters in quiescent ulcerative colitis: are these potential normalization criteria? Int J Mol Sci 2020;21.
Zielińska AK, Sałaga M, Siwiński P, Włodarczyk M, Dziki A, Fichna J. Oxidative stress does not influence subjective pain sensation in inflammatory bowel disease patients. Antioxidants (Basel) 2021;10.
Olén O, Erichsen R, Sachs MC et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 2020;395:123–131.
pubmed: 31929014
doi: 10.1016/S0140-6736(19)32545-0